CG ONCOLOGY, INC. COMMON STOCK
NASDAQ: CGON (CG Oncology, Inc.)
Kemas kini terakhir: 8 jam lalu75.10
0.25 (0.33%)
| Penutupan Terdahulu | 74.85 |
| Buka | 74.97 |
| Jumlah Dagangan | 598,423 |
| Purata Dagangan (3B) | 1,053,675 |
| Modal Pasaran | 6,656,891,904 |
| Harga / Jualan (P/S) | 1.11 |
| Harga / Buku (P/B) | 5.75 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -81,161.54% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -90.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.15% |
| Nisbah Semasa (MRQ) | 30.97 |
| Aliran Tunai Operasi (OCF TTM) | -81.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.18 M |
| Pulangan Atas Aset (ROA TTM) | -12.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CG Oncology, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.17 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.17% |
| % Dimiliki oleh Institusi | 105.34% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |